KRT1 antibody (Cytokeratin 1) (pan)

Details for Product anti-KRT1 Antibody No. ABIN114573, Supplier: Log in to see
Antigen
  • CK1
  • EHK
  • EHK1
  • EPPK
  • K1
  • KRT1A
  • NEPPK
  • Krt-2.1
  • Krt2-1
  • Krt86
  • KRT1
  • Kb1
  • KER1
  • CK-1
  • Keratin-1
  • EpK
  • cytok
  • cytokeratin
  • epi-keratin
  • epiker
  • xK81
  • keratin 1
  • Keratin, type I cytoskeletal 47 kDa
  • KRT1
  • Krt1
  • xk81a1
Epitope
pan
51
34
7
6
5
5
4
4
4
3
2
2
2
2
2
1
1
1
1
1
1
1
1
Reactivity
Human
501
198
174
131
95
79
73
70
70
63
63
57
35
30
5
4
3
3
3
2
2
1
1
1
1
1
1
1
1
1
Host
Mouse
461
64
8
Clonality (Clone)
Monoclonal ()
Conjugate
This KRT1 antibody is un-conjugated
25
24
19
18
17
17
17
17
17
17
17
17
16
16
15
15
15
9
4
1
1
Application
Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))
391
249
232
166
157
154
131
75
28
11
11
2
2
2
2
1
1
Options
Supplier
Log in to see
Supplier Product No.
Log in to see
Request

Get this product for free

It's quick and easy to submit your validation proposal. I want to validate this product

Learn more

Immunogen Cytokeratins from human breast carcinoma cell line MCF-7 and detergent insoluble fraction of psoriatic epidermis.
Clone Cocktail
Isotype Cocktail
Purification Supernatant
Alternative Name Cytokeratin (KRT1 Antibody Abstract)
Background This antibody is a cocktail of two different clones, 5D3 andLP53.Synonyms: Cytokeratin pan-reactive, pan Keratin
Research Area Signaling, Cytoskeleton, Cytokeratins, Extracellular Matrix
Application Notes Immunohistochemistry on paraffin embedded sections: diluted of 1: 15-1: 50 in an ABCmethod (30 minutes at room temperature)Proteolytic digestion of tissue sections is required prior to immunostaining. Positive Control: Skin
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.
Restrictions For Research Use only
Format Liquid
Handling Advice Avoid repeated freezing and thawing.
Storage 4 °C/-20 °C
Storage Comment Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.
Background publications Henze, Fengler, Hartmann, Kornhuber, Janka-Schaub, Niethammer, Riehm: "Six-year experience with a comprehensive approach to the treatment of recurrent childhood acute lymphoblastic leukemia (ALL-REZ BFM 85). A relapse study of the BFM group." in: Blood, Vol. 78, Issue 5, pp. 1166-72, 1991 (PubMed).

Angus, Kiberu, Purvis, Wilkinson, Horne: "Cytokeratins in cervical dysplasia and neoplasia: a comparative study of immunohistochemical staining using monoclonal antibodies NCL-5D3, CAM 5.2, and PKK1." in: The Journal of pathology, Vol. 155, Issue 1, pp. 71-5, 1988 (PubMed).

Moll, Franke, Schiller, Geiger, Krepler: "The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells." in: Cell, Vol. 31, Issue 1, pp. 11-24, 1983 (PubMed).

Gatter, Abdulaziz, Beverley, Corvalan, Ford, Lane, Mota, Nash, Pulford, Stein, Taylor-Papadimitriou, Woodhouse, Mason: "Use of monoclonal antibodies for the histopathological diagnosis of human malignancy." in: Journal of clinical pathology, Vol. 35, Issue 11, pp. 1253-67, 1983 (PubMed).